The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results.
V. Gregorc
No relevant relationships to disclose
N. Zilembo
No relevant relationships to disclose
F. Grossi
No relevant relationships to disclose
G. Rossoni
No relevant relationships to disclose
F. Pietrantonio
No relevant relationships to disclose
E. Rijavec
No relevant relationships to disclose
A. Bulotta
No relevant relationships to disclose
M. Vitali
No relevant relationships to disclose
G. Barletta
No relevant relationships to disclose
L. Bergamaschi
No relevant relationships to disclose
M. Platania
No relevant relationships to disclose
F. Caligaris-Cappio
No relevant relationships to disclose
A. Lambiase
Employment or Leadership Position - MolMed S.p.A.
C. Bordignon
Employment or Leadership Position - MolMed S.p.A.